11 the cascade · 0 complete · 11 partly written · 0 not yet written
The cascade
The screening cascade as one walk-through, from disease to clinic. At each step: what is done, what it costs, what it proves and what it cannot.
Record
-
1. Disease and phenotype target-id For a rare disease: define the phenotype, sequence the patient (often with family), filter the variants and classify them. That the gene is a drug target: a diagnosis explains one patient's disease, and 11.3% of the same children carried variants of uncertain significance. partly written
-
2. GWAS and variant prioritisation target-id Two different activities. Which variant is causal, which gene it acts on, and which direction a drug should push. partly written
-
3. Target and gene module target-id Fine-mapping narrows a locus to candidate variants; colocalisation with expression data and locus-to-gene models nominate a gene; rare-variant burden tests and Mendelian randomisation add gene-level evidence. That the gene call is right or that the drug direction is known. partly written
-
4. Pathways and interaction partners target-id not yet written That the interaction happens in a living cell at real concentrations, how long it lasts, or that a screen-only pair belongs to a pathway. partly written
-
5. Hit discovery hit-discovery Find compounds that move the target's readout. That the compound binds the target, acts through it, is selective, or does anything in a cell. partly written
-
6. High-throughput screening hit-discovery Robots deliver a tiny, identical amount of each compound to every well of a plate and an assay reads the result. That a hit is real: a good Z-prime says the controls are separated, not that the hits are genuine. partly written
-
7. Dose response hit-to-lead Each hit is tested across a series of concentrations and a four-parameter curve (bottom, top, midpoint, slope) is fitted; the midpoint is reported as an IC50 or EC50. Affinity: for a competitive inhibitor Ki = IC50 / (1 + [S]/Km), so the IC50 moves with substrate level. partly written
-
8. Mechanism-confirmation assays hit-to-lead Independent evidence that the compound binds this target and reaches it in a living cell. Function: a binder can be inert or bind an irrelevant site, and SPR kinetic fits can look convincing and be wrong. partly written
-
9. Medicinal chemistry: potency, selectivity, ADMET lead-optimisation A loop: edit a molecule slightly, measure potency, selectivity and properties, keep what helps. That the compound is selective beyond its panel: ten cancer drugs still killed cells after CRISPR deletion of the supposed target, and 243 clinical kinase drugs showed widespread polypharmacology including non-kinase… partly written
-
11. Preclinical preclinical Laboratory-animal and in vitro studies of pharmacology, drug disposition and toxicology, on which the sponsor concludes it is reasonably safe to start human trials. Safety in humans where the animal model lacks the human target or cell type. partly written
-
12. Clinical clinical Testing in people in phases defined by regulation. That a measured change in the target means benefit: tominersen lowered mutant huntingtin in spinal fluid and the every-2-months arm still did worse than placebo (see the modality notes). partly written